{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:03:16Z","timestamp":1794873796327,"version":"4.9.1"},"reference-count":43,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,9,15]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate whether very high disease activity (VHDA) status or severe symptoms when in HDA state predict residual disease after achieving inactive disease\/low disease activity (ID\/LDA) in axial spondyloarthritis (axSpA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective data from the SpA-Net registry were used. HDA was defined as an Axial Spondyloarthritis Disease Activity Score (ASDAS) \u2265 2.1, and ID\/LDA as ASDAS &lt; 2.1. VHDA (predictor 1) was defined as ASDAS &gt; 3.5, and severe symptoms when in HDA state (predictor 2) as a score \u2265 6\/10 for fatigue, back pain, and\/or physical function. Residual disease (outcome) was defined as presence of \u2265 1 patient-experienced (fatigue, back pain, and\/or physical function \u2265 4\/10) or objective disease indicator (active peripheral manifestations, active psoriasis, elevated C-reactive protein, or physician global assessment) after achieving ID\/LDA. Associations between either predictor and residual disease were investigated using logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 133 patients (58 [43.6%] female, mean age 48.8 [SD 14.5] years) were included. At the HDA timepoint, 16 (12%) patients had VHDA status and 107 (80.5%) experienced severe symptoms. At the ID\/LDA timepoint, prevalence of patient-experienced and objective residual disease was 70.7% (n = 94\/133) and 54% (n = 37\/68), respectively. VHDA status when in HDA state was not associated with either form of residual disease after achieving ID\/LDA. Severe symptoms were associated with patient-experienced residual disease (odds ratio 5.09, 95% CI 1.76-14.71), but not objective residual disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Severe symptoms when in HDA state predict patient-experienced, but not objective, residual disease in axSpA, whereas VHDA status does not predict either form. These findings may aid in anticipating residual disease and guiding management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0421","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:25:13Z","timestamp":1759321513000},"page":"386-394","source":"Crossref","is-referenced-by-count":1,"title":["Predictive Value of Severe Symptoms for Residual Disease After Transitioning From High to Low Disease Activity in Axial Spondyloarthritis: A Longitudinal Study"],"prefix":"10.3899","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0039-493X","authenticated-orcid":false,"given":"Marius L.","family":"Smits","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2640-0746","authenticated-orcid":false,"given":"Ellen","family":"Renet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3792-7718","authenticated-orcid":false,"given":"Harald E.","family":"Vonkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-8547","authenticated-orcid":false,"given":"Casper","family":"Webers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8477-0683","authenticated-orcid":false,"given":"Astrid","family":"van Tubergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"2026040105300589000_53.4.386.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"2026040105300589000_53.4.386.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209209"},{"key":"2026040105300589000_53.4.386.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094870"},{"key":"2026040105300589000_53.4.386.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138594"},{"key":"2026040105300589000_53.4.386.5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0140-6736(24)02263-3","article-title":"Axial spondyloarthritis","volume":"405","author":"Navarro-Comp\u00e1n","year":"2025","journal-title":"Lancet"},{"key":"2026040105300589000_53.4.386.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"2026040105300589000_53.4.386.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-0194"},{"key":"2026040105300589000_53.4.386.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200934"},{"key":"2026040105300589000_53.4.386.9","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.3390\/jcm11123553","article-title":"Residual disease in patients with axial spondyloarthritis: a post-hoc analysis of the QUASAR study","volume":"11","author":"D\u2019Angelo","year":"2022","journal-title":"J Clin Med"},{"key":"2026040105300589000_53.4.386.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216143"},{"key":"2026040105300589000_53.4.386.11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002663"},{"key":"2026040105300589000_53.4.386.12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000860"},{"key":"2026040105300589000_53.4.386.13","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2026040105300589000_53.4.386.14","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol"},{"key":"2026040105300589000_53.4.386.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew238"},{"key":"2026040105300589000_53.4.386.16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151244"},{"key":"2026040105300589000_53.4.386.17","doi-asserted-by":"crossref","first-page":"e15418","DOI":"10.1111\/1756-185X.15418","article-title":"Defining objective BASDAI cut-offs for disease activity states and improvement scores in axial spondyloarthritis: a multicentric collaboration","volume":"27","author":"Goswami","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"2026040105300589000_53.4.386.18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.rdc.2016.01.011","article-title":"Patient-reported outcomes in axial spondyloarthritis","volume":"42","author":"Nhan","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"2026040105300589000_53.4.386.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"2026040105300589000_53.4.386.20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.reuma.2024.10.002","article-title":"Do patients with axial spondyloarthritis with active disease suffer from greater disease burden and work impairment? Results from the international map of axial spondyloarthritis (IMAS)","volume":"20","author":"Garrido-Cumbrera","year":"2024","journal-title":"Reumatol Clin"},{"key":"2026040105300589000_53.4.386.21","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/acr.25436","article-title":"Low socioeconomic status and female sex are associated with worse functional status in axial spondyloarthritis","volume":"77","author":"Stovall","year":"2025","journal-title":"Arthritis Care Res"},{"key":"2026040105300589000_53.4.386.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212076"},{"key":"2026040105300589000_53.4.386.23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1477-7525-9-36","article-title":"Psychometric characteristics of the Short Form 36 Health Survey and functional assessment of chronic illness therapy-fatigue subscale for patients with ankylosing spondylitis","volume":"9","author":"Revicki","year":"2011","journal-title":"Health Qual Life Outcomes"},{"key":"2026040105300589000_53.4.386.24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00296-018-4200-4","article-title":"Evaluation of the performance of extreme patient-reported outcomes as surrogate markers for fibromyalgia in axial spondyloarthritis","volume":"39","author":"Santos-Faria","year":"2019","journal-title":"Rheumatol Int"},{"key":"2026040105300589000_53.4.386.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152078"},{"key":"2026040105300589000_53.4.386.26","doi-asserted-by":"publisher","DOI":"10.2340\/16501977-1104"},{"key":"2026040105300589000_53.4.386.27","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/acr.23566","article-title":"The impact of illness perceptions and coping on the association between back pain and health outcomes in patients suspected of having axial spondyloarthritis: data from the spondyloarthritis caught early cohort","volume":"70","author":"van Lunteren","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2026040105300589000_53.4.386.28","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-00541-7"},{"key":"2026040105300589000_53.4.386.29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa888"},{"key":"2026040105300589000_53.4.386.30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/rheumatology\/kead634","article-title":"Factors associated with treatment intensification in patients with axial spondyloarthritis and high disease activity in clinical practice","volume":"64","author":"Webers","year":"2025","journal-title":"Rheumatology"},{"key":"2026040105300589000_53.4.386.31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00296-025-06011-1","article-title":"Which ASDAS cut-off corresponds best to treatment intensification in patients with axial spondyloarthritis in daily practice? A prospective study from a clinical registry","volume":"45","author":"Nezam El-Din","year":"2025","journal-title":"Rheumatol Int"},{"key":"2026040105300589000_53.4.386.32","doi-asserted-by":"crossref","first-page":"e0230317","DOI":"10.1371\/journal.pone.0230317","article-title":"Discordance between the patient\u2019s and physician\u2019s global assessment in rheumatoid arthritis: data from the REAL study-Brazil","volume":"15","author":"Guimar\u00e3es","year":"2020","journal-title":"PLoS One"},{"key":"2026040105300589000_53.4.386.33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/acr.25246","article-title":"Patients\u2019 perspectives on axial pain in relation to inflammation and structural damage in a large cohort of axial spondyloarthritis patients","volume":"76","author":"Kampman","year":"2024","journal-title":"Arthritis Care Res"},{"key":"2026040105300589000_53.4.386.34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00296-025-05795-6","article-title":"Barriers and facilitators to treat-to-target in axial spondyloarthritis in clinical practice: a mixed methods study","volume":"45","author":"Smits","year":"2025","journal-title":"Rheumatol Int"},{"key":"2026040105300589000_53.4.386.35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160104"},{"key":"2026040105300589000_53.4.386.36","doi-asserted-by":"crossref","first-page":"rkad084","DOI":"10.1093\/rap\/rkad084","article-title":"Prevalence and factors associated with fatigue in patients with axial spondyloarthritis: a systematic review and meta-analysis","volume":"7","author":"Tang","year":"2023","journal-title":"Rheumatol Adv Pract"},{"key":"2026040105300589000_53.4.386.37","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150463"},{"key":"2026040105300589000_53.4.386.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212377"},{"key":"2026040105300589000_53.4.386.39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-018-1556-5","article-title":"Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial","volume":"20","author":"van der Heijde","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2026040105300589000_53.4.386.40","doi-asserted-by":"publisher","DOI":"10.1186\/ar4464"},{"key":"2026040105300589000_53.4.386.41","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004369"},{"key":"2026040105300589000_53.4.386.42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214199"},{"key":"2026040105300589000_53.4.386.43","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40744-021-00289-w","article-title":"A novel qualitative study assessing patient-reported outcome measures among people living with psoriatic arthritis or ankylosing spondylitis","volume":"8","author":"Chakravarty","year":"2021","journal-title":"Rheumatol Ther"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T12:30:29Z","timestamp":1775046629000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,1]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.3899\/jrheum.2025-0421"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0421","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}